Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
J Virol. 1993 Oct; 67(10): 5843–5848.
PMCID: PMC238002

Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.


The antibody response to a previously defined B-cell epitope of Semliki Forest virus (SFV) was investigated in male BALB/c (H-2d) mice. The B-cell epitope, located at amino acid positions 240 to 255 of the E2 protein, was linked to an H-2d-restricted T-helper cell epitope of SFV located at positions 137 to 151 of the E2 protein. Colinearly synthesized peptides, of either T-B or B-T polarity, mixed with different adjuvants (the nonionic block copolymer L 180.5, a water-oil-water [W/O/W] emulsion of L 180.5, Montanide, and Q VAC) were used for immunization. Generally, after one booster immunization, high serum antibody titers were measured against either peptide. With Q VAC and W/O/W L 180.5 as adjuvants, the titers of SFV-reactive (nonneutralizing) antibodies were consistently much higher after immunization with the T-B peptide than with the B-T peptide, which was reflected in a higher vaccine efficacy. With these two adjuvants, the survival ratio in T-B peptide-immunized mice was 82%, compared with 8% in B-T peptide-immunized mice. Intermediate results were obtained with the adjuvant Montanide. L 180.5 alone was ineffective in this study. All immunoglobulin G (IgG) isotypes were induced with either adjuvant, but Q VAC was clearly the most effective in inducing IgG2a and IgG2b isotypes with the T-B peptide as the antigen. Subsequently, monoclonal antibodies (MAbs) of IgM, IgG1, IgG2a, IgG2b, and IgG3 subclasses were prepared against the B-cell epitope. These nonneutralizing but SFV-reactive MAbs protected 40 to 80% of mice against a lethal challenge with SFV. Control mice all died. The availability of those antipeptide MAbs allowed competition binding assays with a previously characterized panel of E2-specific MAbs. Binding of enzyme-labeled antipeptide MAbs was very effectively inhibited by two strongly SFV-neutralizing mutually competitive MAbs, suggesting that the linear B-cell epitope (amino acids 240 to 255) is associated with a major neutralization site of SFV.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Methods. 1986 Dec 24;95(2):157–168. [PubMed]
  • Allison AC, Byars NE. Immunological adjuvants: desirable properties and side-effects. Mol Immunol. 1991 Mar;28(3):279–284. [PubMed]
  • Barteling SJ, Vreeswijk J. Developments in foot-and-mouth disease vaccines. Vaccine. 1991 Feb;9(2):75–88. [PubMed]
  • Boere WA, Benaissa-Trouw BJ, Harmsen T, Erich T, Kraaijeveld CA, Snippe H. Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus. J Virol. 1985 May;54(2):546–551. [PMC free article] [PubMed]
  • Boere WA, Harmsen T, Vinjé J, Benaissa-Trouw BJ, Kraaijeveld CA, Snippe H. Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities. J Virol. 1984 Nov;52(2):575–582. [PMC free article] [PubMed]
  • Bradish CJ, Allner K, Maber HB. The virulence of original and derived strains of Semliki forest virus for mice, guinea-pigs and rabbits. J Gen Virol. 1971 Aug;12(2):141–160. [PubMed]
  • Cox JH, Ivanyi J, Young DB, Lamb JR, Syred AD, Francis MJ. Orientation of epitopes influences the immunogenicity of synthetic peptide dimers. Eur J Immunol. 1988 Dec;18(12):2015–2019. [PubMed]
  • Dalsgaard K. Adjuvants. Vet Immunol Immunopathol. 1987 Dec;17(1-4):145–152. [PubMed]
  • Faragher SG, Meek AD, Rice CM, Dalgarno L. Genome sequences of a mouse-avirulent and a mouse-virulent strain of Ross River virus. Virology. 1988 Apr;163(2):509–526. [PubMed]
  • Garoff H, Frischauf AM, Simons K, Lehrach H, Delius H. Nucleotide sequence of cdna coding for Semliki Forest virus membrane glycoproteins. Nature. 1980 Nov 20;288(5788):236–241. [PubMed]
  • Golvano J, Lasarte JJ, Sarobe P, Gullón A, Prieto J, Borrás-Cuesta F. Polarity of immunogens: implications for vaccine design. Eur J Immunol. 1990 Oct;20(10):2363–2366. [PubMed]
  • Hadjipetrou-Kourounakis L, Möller E. Adjuvants influence the immunoglobin subclass distribution of immune responses in vivo. Scand J Immunol. 1984 Mar;19(3):219–225. [PubMed]
  • Hocart MJ, Mackenzie JS, Stewart GA. The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies. J Gen Virol. 1989 Sep;70(Pt 9):2439–2448. [PubMed]
  • Hunt AR, Short WA, Johnson AJ, Bolin RA, Roehrig JT. Synthetic peptides of the E2 glycoprotein of Venezuelan equine encephalomyelitis virus. II. Antibody to the amino terminus protects animals by limiting viral replication. Virology. 1991 Nov;185(1):281–290. [PubMed]
  • Hunter R, Olsen M, Buynitzky S. Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody. Vaccine. 1991 Apr;9(4):250–256. [PubMed]
  • Karagouni EE, Hadjipetrou-Kourounakis L. Regulation of isotype immunoglobulin production by adjuvants in vivo. Scand J Immunol. 1990 Jun;31(6):745–754. [PubMed]
  • Kenney JS, Hughes BW, Masada MP, Allison AC. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J Immunol Methods. 1989 Jul 26;121(2):157–166. [PubMed]
  • Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol. 1991 Jan 15;146(2):431–437. [PubMed]
  • Levine B, Hardwick JM, Trapp BD, Crawford TO, Bollinger RC, Griffin DE. Antibody-mediated clearance of alphavirus infection from neurons. Science. 1991 Nov 8;254(5033):856–860. [PubMed]
  • McKendall RR, Woo W. Murine IgG subclass responses to herpes simplex virus type 1 and polypeptides. J Gen Virol. 1988 Apr;69(Pt 4):847–857. [PubMed]
  • Nakane PK, Kawaoi A. Peroxidase-labeled antibody. A new method of conjugation. J Histochem Cytochem. 1974 Dec;22(12):1084–1091. [PubMed]
  • Oosterlaken TA, Vlaspolder F, Fransen R, Harmsen T, Kraaijeveld CA, Snippe H. Competition binding assay in cell culture for identification of epitopes on enveloped and naked viruses. Zentralbl Bakteriol. 1989 Jul;271(2):237–243. [PubMed]
  • Partidos C, Stanley C, Steward M. The influence of orientation and number of copies of T and B cell epitopes on the specificity and affinity of antibodies induced by chimeric peptides. Eur J Immunol. 1992 Oct;22(10):2675–2680. [PubMed]
  • Schmaljohn AL, Johnson ED, Dalrymple JM, Cole GA. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature. 1982 May 6;297(5861):70–72. [PubMed]
  • Snijders A, Benaissa-Trouw BJ, Oosterlaken TA, Puijk WC, Posthumus WP, Meloen RH, Boere WA, Oosting JD, Kraaijeveld CA, Snippe H. Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine. J Gen Virol. 1991 Mar;72(Pt 3):557–565. [PubMed]
  • Snijders A, Benaissa-Trouw BJ, Snippe H, Kraaijeveld CA. Immunogenicity and vaccine efficacy of synthetic peptides containing Semliki Forest virus B and T cell epitopes. J Gen Virol. 1992 Sep;73(Pt 9):2267–2272. [PubMed]
  • Snijders A, Benaissa-Trouw BJ, Visser-Vernooy HJ, Fernandez I, Snippe H, Kraaijeveld CA. A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production. Immunology. 1992 Nov;77(3):322–329. [PMC free article] [PubMed]
  • Vlaspolder F, Kraaijeveld CA, van Buuren R, Harmsen M, Benaissa-Trouw BJ, Snippe H. Prophylaxis and therapy of virulent encephalomyocarditis virus infection in mice by monoclonal antibodies. Brief report. Arch Virol. 1988;98(1-2):123–130. [PubMed]
  • Vrati S, Fernon CA, Dalgarno L, Weir RC. Location of a major antigenic site involved in Ross River virus neutralization. Virology. 1988 Feb;162(2):346–353. [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...